Innovate UK, part of UK Research and Innovation, today welcomed the announcement that immunotherapy company, TCR2 Therapeutics, is to become the first US organisation to work with the Cell and Gene Therapy (CGT) Catapult at its Stevenage manufacturing centre.
TCR2 has selected the facility to establish a site for global manufacturing and capability development to advance novel T cell receptor therapies for patients suffering from cancer.
Dr Ian Campbell, Interim Executive Chair, Innovate UK said: “By choosing to work with the Cell & Gene Therapy Catapult manufacturing centre, TCR2 Therapeutics demonstrates to the world that the UK is a global leader in this sector. Advanced cell and gene therapies show great promise in treating conditions such as cancer. It is vital to support research and development that could result in huge improvements in patient outcomes.
“Boosted by investment through the government’s modern Industrial Strategy and the life sciences sector deal, the UK can realise both the commercial and societal benefits from these advances in this vital and thriving sector.”
The CGT Catapult manufacturing centre in Stevenage, opened in April 2018, is backed by more than £60m of government investment, including funding from Innovate UK and the Industrial Strategy Challenge Fund (ISCF). TCR2 joins advanced therapy companies Adaptimmune, Autolus, Cell Medica, and Freeline.